Products
Pre-Made Bevifimod biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Staphylococcal protein A for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-758
Pre-Made Bevifimod biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Staphylococcal protein A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Preferred Name: Bevifimod
Definition: A proprietary formulation containing a highly purified form of Staphylococcal protein A (SpA; protein A), with potential immunomodulating activity. Upon administration of bevifimod, this protein is able to specifically bind to both the subset of B-lymphocytes that express the heavy chain variable region 3 (VH3)-encoded immunoglobulin (Ig) (VH3-B-cells) and macrophages. This prevents B-cell activation, induces apoptosis, prevents VH3-derived antibody formation, antibody-mediated immune responses, and destruction by macrophages. This may modulate specific immune signaling pathways and restore normal immune system functions caused by certain immune-mediated inflammatory diseases. In patients with the autoimmune-mediated disease immune thrombocytopenia (ITP), PRTX-100 prevents destruction of platelets, increases platelet production and platelet blood levels, and decreases the risk of bleeding. SpA, a 42 kDa bacterial membrane protein produced by Staphylococcus aureus bacteria, consists of five nearly identical Ig binding domains; each SpA domain binds with high affinity to the Igs containing regions encoded by the VH3 gene family. B-lymphocytes that express VH3-encoded Igs are specifically involved in various auto-immune diseases.
Immunoglobulin (Ig) G molecules are essential players in the human immune response against bacterial infections. An important effector of IgG-dependent immunity is the induction of complement activation, a reaction that triggers a variety of responses that help kill bacteria. Antibody-dependent complement activation is promoted by the organization of target-bound IgGs into hexamers that are held together via noncovalent Fc-Fc interactions. BEVIFIMOD, staphylococcal protein A (SpA) is an important virulence factor and vaccine candidate of Staphylococcus aureus, effectively blocks IgG hexamerization and subsequent complement activation.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-758-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-758-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-758-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-758-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Bevifimod biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting Staphylococcal protein A |
| INN Name | Bevifimod |
| Target | Staphylococcal protein A |
| Format | Recombinant Protein |
| Derivation | Staphylococcus aureus |
| Species Reactivity | human |
| CH1 Isotype | staphylococcal protein A (SpA) |
| VD LC | staphylococcal protein A (SpA) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Protalex, Inc. (Florham Park NJ USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
